Iambic Presents Updated Iam1363 Clinical Data At Esmo 2026, Showing Durable Responses With A Favorable Tolerability Profile In Heavily Pretreated Participants With Her2-Driven Cancers
Ler o artigo completo
Tenha acesso ilimitado aos artigos da Reuters e de todas as outras fontes de notícias no TradingView.